6MW3211 + azacitidine + venetoclax

This drug is a **combination therapy** of three agents: - **6MW3211**: A bispecific IgG-like monoclonal antibody designed to simultaneously target CD47 and PD-L1 on tumor cells. It inhibits the **CD47-SIRPα** ("don't eat me" signal) and **PD-1/PD-L1** ("don't find me" signal) immune checkpoints, resulting in enhanced macrophage-mediated phagocytosis and T cell activation against cancer cells. Uniquely, it uses a common light chain strategy for stability and manufacturing and is engineered to minimize binding to erythrocytes, potentially reducing blood toxicity. Developed by Mabwell for the treatment of advanced solid and hematological tumors[1][3][5]. - **Azacitidine**: A hypomethylating agent and nucleoside analog that incorporates into DNA/RNA and leads to **epigenetic reactivation of tumor suppressor genes** and promotion of cellular differentiation or apoptosis. Used primarily in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)[2][4][6]. - **Venetoclax**: An orally bioavailable small molecule selective **BCL-2 (B-cell lymphoma 2) inhibitor**, which induces apoptosis in cancer cells dependent on BCL-2 for survival. Primarily used in AML, MDS, and chronic lymphocytic leukemia (CLL)[2][4][6]. This combination is being developed/explored for synergistic antitumor effects via: - Dual checkpoint blockade (CD47 + PD-L1) - DNA hypomethylation/restoration of normal cell regulation (azacitidine) - Induction of tumor cell apoptosis (venetoclax)